139 related articles for article (PubMed ID: 22677920)
1. Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.
Vaneckova M; Kalincik T; Krasensky J; Horakova D; Havrdova E; Hrebikova T; Seidl Z
Eur Neurol; 2012; 68(1):23-7. PubMed ID: 22677920
[TBL] [Abstract][Full Text] [Related]
2. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
3. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
4. Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis.
Rocca MA; Absinta M; Moiola L; Ghezzi A; Colombo B; Martinelli V; Comi G; Filippi M
Radiology; 2010 Feb; 254(2):541-50. PubMed ID: 20093525
[TBL] [Abstract][Full Text] [Related]
5. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
6. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
7. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
9. Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Granberg T; Martola J; Bergendal G; Shams S; Damangir S; Aspelin P; Fredrikson S; Kristoffersen-Wiberg M
Mult Scler; 2015 Aug; 21(9):1151-8. PubMed ID: 25480866
[TBL] [Abstract][Full Text] [Related]
10. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
Rudick RA; Lee JC; Simon J; Fisher E
Ann Neurol; 2006 Aug; 60(2):236-42. PubMed ID: 16786526
[TBL] [Abstract][Full Text] [Related]
11. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
12. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.
Yaldizli Ö; Penner IK; Frontzek K; Naegelin Y; Amann M; Papadopoulou A; Sprenger T; Kuhle J; Calabrese P; Radü EW; Kappos L; Gass A
Mult Scler; 2014 Mar; 20(3):356-64. PubMed ID: 23959709
[TBL] [Abstract][Full Text] [Related]
13. Immune cell NT-3 expression is associated with brain atrophy in multiple sclerosis patients.
Kalinowska-Łyszczarz A; Pawlak MA; Michalak S; Paprzycki W; Losy J
J Neuroimmunol; 2011 Dec; 240-241():109-13. PubMed ID: 22036954
[TBL] [Abstract][Full Text] [Related]
14. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
15. 'Importance sampling' in MS: use of diffusion tensor tractography to quantify pathology related to specific impairment.
Lin X; Tench CR; Morgan PS; Niepel G; Constantinescu CS
J Neurol Sci; 2005 Oct; 237(1-2):13-9. PubMed ID: 16109428
[TBL] [Abstract][Full Text] [Related]
16. Dichotic listening and corpus callosum magnetic resonance imaging in relapsing-remitting multiple sclerosis with emphasis on sex differences.
Gadea M; Marti-Bonmatí L; Arana E; Espert R; Casanova V; Pascual A
Neuropsychology; 2002 Apr; 16(2):275-81. PubMed ID: 11949719
[TBL] [Abstract][Full Text] [Related]
17. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.
Zhang Y; Metz LM; Yong VW; Mitchell JR
J Neurol Sci; 2010 Oct; 297(1-2):76-81. PubMed ID: 20708201
[TBL] [Abstract][Full Text] [Related]
18. Shape analysis of the corpus callosum and cerebellum in female MS patients with different clinical phenotypes.
Sigirli D; Ercan I; Ozdemir ST; Taskapilioglu O; Hakyemez B; Turan OF
Anat Rec (Hoboken); 2012 Jul; 295(7):1202-11. PubMed ID: 22585536
[TBL] [Abstract][Full Text] [Related]
19. Brain atrophy as a marker of cognitive impairment in mildly disabling relapsing-remitting multiple sclerosis.
Sánchez MP; Nieto A; Barroso J; Martín V; Hernández MA
Eur J Neurol; 2008 Oct; 15(10):1091-9. PubMed ID: 18727673
[TBL] [Abstract][Full Text] [Related]
20. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
Korteweg T; Rovaris M; Neacsu V; Filippi M; Comi G; Uitdehaag BM; Knol DL; Polman CH; Barkhof F; Vrenken H;
Mult Scler; 2009 Apr; 15(4):465-71. PubMed ID: 19091881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
